COLL Gains on ADHD Portfolio
Collegium Pharmaceutical's attention deficit hyperactivity disorder portfolio is gaining attention, driving the stock higher. The company's focus on ADHD treatments is a key factor in its growth.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.